Asarina Pharma Q4’20: First Comment

Research Note

2021-02-25

11:26

In Asarina Pharma’s Q4’20 report, we are encouraged to see cost measures taken to readout two phase 2 studies: menstrual migraine (MM) and Tourette’s Syndrome (Tourettes), with the current cash position. The top-line results in MM move nearer, and we see an increasing rationale with sepranolone in Tourettes. In other words, interesting times ahead.

AH

Anders Hedlund

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.